摘要
背景:miR-146a和miR-155是先天性免疫反应的关键调控因子。我们假设唐氏综合征(DS)和阿尔茨海默病(AD)患者可能发生炎症介导的这些miRNA失调。 方法:通过原位杂交研究对照,DS患者和AD病理学成年人(DS和散发性AD; sAD)的海马中的miRNA表达模式。采用定量实时定量PCR检测sAD海马组织和DS和AD小鼠模型的miRNA水平。两种miRNA都在产前人类海马中表达。在DS中,我们检测到反应性星形胶质细胞中miR-146a表达增加。在sAD的海马中发现miR-146a的表达增加,并且与其靶IRAK-1呈负相关。与WT和3个月的小鼠相比,APP / PS1小鼠在11-13个月龄时显示出两种miRNA的表达显着增加。在Ts65Dn和APP / PS1小鼠中观察到miR-146a水平与其靶TRAF6之间的负相关。 结论:这些发现提示miR-146a和miR-155可能参与脑发育和神经退行性病变。具体而言,我们提供了AD中这两种免疫调节性miRNA失调的证据,其具有潜在的治疗意义,值得进一步研究。
关键词: 海马,发育,唐氏综合症,阿尔茨海默氏病,Ts65Dn-APP / PS1,microRNA。
Current Alzheimer Research
Title:Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Volume: 14 Issue: 12
关键词: 海马,发育,唐氏综合症,阿尔茨海默氏病,Ts65Dn-APP / PS1,microRNA。
摘要: Background: miR-146a and miR-155 are key regulators of the innate immune response. We hypothesized that an inflammation-mediated dysregulation of these miRNAs may occur in patients with Down syndrome (DS) and Alzheimer's disease (AD).
Methods: The miRNA expression patterns were investigated by in situ hybridization in developing hippocampus from controls, patients with DS and in adults with AD pathology (DS and sporadic AD; sAD). Quantitative real-time PCR was employed to evaluate the miRNA levels in the hippocampus of sAD and in mouse models of DS and AD. Both miRNAs were expressed in prenatal human hippocampus. In DS we detected increased miR-146a expression in reactive astrocytes. Increased expression of miR-146a was found in the hippocampus of sAD and negatively correlated with its target IRAK-1. APP/PS1 mice showed a significant increase in the expression of both miRNAs at 11-13 months of age as compared to WT and mice at 3 months. A negative correlation between miR-146a levels and its target TRAF6 was observed in both Ts65Dn and APP/PS1 mice.
Conclusion: These findings suggest a possible involvement of miR-146a and miR-155 in brain development and neurodegeneration. In particular, we provide evidence of a dysregulation of these two immunomodulatory miRNAs in AD with a potential therapeutical implication, deserving further investigation.
Export Options
About this article
Cite this article as:
Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease, Current Alzheimer Research 2017; 14 (12) . https://dx.doi.org/10.2174/1567205014666170706112701
DOI https://dx.doi.org/10.2174/1567205014666170706112701 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnology and Brain Tumors Drug Delivery
Recent Patents on Nanomedicine 1-O-Octadecyl-2-O-Methylglycero-3-phosphocholine (Edelfosine) and Cancer Cell Invasion: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design Growth Retardation of Poorly Transfectable Tumor by Multiple Injections of Plasmids Encoding PE40 Based Targeted Toxin Complexed with Polyethylenimine
Current Gene Therapy Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Radiochemical Evaluation and <i>In Vitro</i> Assessment of the Targeting Ability of a Novel <sup>99m</sup>Tc-HYNIC-RGD for U87MG Human Brain Cancer Cells
Current Radiopharmaceuticals Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Chemical Consequences of Radioactive Decay and their Biological Implications
Current Radiopharmaceuticals Subject Index to Volume 7
Combinatorial Chemistry & High Throughput Screening Recent Advances in the Development of Thioredoxin Reductase Inhibitors as Anticancer Agents
Current Drug Targets Novel Biomarkers of microRNAs in Gastric Cancer: An Overview from Diagnosis to Treatment
MicroRNA Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Targeting the Mevalonate Pathway for Improved Anticancer Therapy
Current Cancer Drug Targets A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry